Lake County reports first case of West Nile virus
An update on the victim's condition was not released. This is the second case of the virus in Illinois reported this year. Last year saw 69 cases across the state, including six in Lake County, according to data from the Illinois Department of Public Health.
Lake County Health Department and Community Health Center Executive Director Chris Hoff advised caution for residents spending more time outdoors during the summer, exposing themselves to mosquitoes, which can carry the virus.
'Remember to take steps to protect yourself and your family from mosquitoes to reduce your risk of getting West Nile virus,' Hoff said.
According to a county release, nine of 214 batches of mosquitoes have tested positive for West Nile virus in 2025. West Nile virus typically peaks during the late summer, usually from July through September when the mosquito population is at its peak, the release said.
The department gave '4 Ds of Defense' for protecting against mosquitoes — drain, defend, dawn to dusk and dress. These include draining any standing water, using EPA-approved insect repellents, using proper protection during prime mosquito activity hours and wearing clothes that cover exposed skin.
According to the release, most people infected with West Nile virus have no symptoms, but some become ill three to 15 days after being bitten by an infected mosquito. Symptoms include fever, nausea, headache and muscle aches.
In rare cases, the virus can affect the brain or spinal cord, leading to 'serious neurological symptoms' such as stiff neck, confusion, sudden weakness or numbness on one side of the body, trouble walking or even death.
Those over 60 and individuals with weakened immune systems or multiple medical conditions are at higher risk for severe illness from West Nile virus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Which states' air quality are most impacted by Canadian wildfires? See map.
As wildfires spread across Canada, air quality in the U.S. continues to be impacted, and people sensitive to air pollution could face "serious health effects," according to a government website that tracks air quality in the United States. There are 59 uncontrolled wildfires and 108 controlled wildfires across Canada as of Wednesday, July 30, the country's National Wildland Fire Situation Report said on its website. To date this year, there have been 3,582 fires. Fires have burned nearly 1.5 million acres since the start of 2025, according to the country's report. The smoke floating over the border shared between America and Canada is now impacting air quality in states as far south as Texas, AirNow's data shows. The EPA has declared the air quality in states near the Canadian border as "unhealthy or "unhealthy for sensitive groups." See maps and impacted states. See map of Canadian wildfires See map of US wildfires and smoke Which states are most affected by the Canadian fires? As of 9 a.m. ET on Tuesday, Aug. 5, areas in the following states are "Unhealthy for sensitive groups," according to AirNow: Montana Wisconsin Michigan Indiana Ohio New York Pennsylvania New Jersey Connecticut Massachusetts Vermont New Hampshire Maine People with pre-existing medical conditions, like asthma, will be more sensitive to conditions that are deemed "Unhealthy for Sensitive Groups." "Members of sensitive groups may experience health effects," according to AirNow. 'Unhealthy' air quality States' air quality is measured by the EPA's U.S. Air Quality Index, according to AirNow's website. Values with an index of 151 to 200 are deemed unhealthy for all. As of 9 a.m. ET on Tuesday, Aug. 5, areas in the following states have been deemed unhealthy, according to AirNow's air quality map: Wisconsin Michigan Vermont "Some members of the general public may experience health effects," AirNow states on its website. However, "members of sensitive groups may experience more serious health effects." To learn if your area's air quality is affected by the wildfires, visit AirNow's interactive map. Side effects of inhaling wildfire smoke Wildfire smoke can irritate one's eyes, nose, and throat and cause the following symptoms: Coughing Chest tightness Shortness of breath Dizziness Fatigue Particulate matter (PM) is one of the main components of wildfire smoke, comprised of small particles of solids or liquids suspended in the air, USA TODAY previously reported. According to Yale Medicine, the particles can be 10 micrometers, PM 10, or as small as 2.5 micrometers, PM 2.5, and the smaller one poses a lot of health risks. PM 2.5 is so tiny that it can easily pass people's usual defense mechanisms and go deep into their lungs. Not only can it damage lung function, but it can also pass into the bloodstream and travel to other organs. The following is linked to exposure to the PM 2.5: Heart attack Stroke Lung cancer Decline in cognitive function Julia is a trending reporter for USA TODAY. Connect with her on LinkedIn, X, Instagram, and TikTok: @juliamariegz, or email her at jgomez@ This article originally appeared on USA TODAY: Air quality map shows US states most impacted by Canadian wildfires
USA Today
2 hours ago
- USA Today
Which states' air quality are most impacted by Canadian wildfires? See map.
As wildfires spread across Canada, air quality in the U.S. continues to be impacted, and people sensitive to air pollution could face "serious health effects," according to a government website that tracks air quality in the United States. There are 59 uncontrolled wildfires and 108 controlled wildfires across Canada as of Wednesday, July 30, the country's National Wildland Fire Situation Report said on its website. To date this year, there have been 3,582 fires. Fires have burned nearly 1.5 million acres since the start of 2025, according to the country's report. The smoke floating over the border shared between America and Canada is now impacting air quality in states as far south as Texas, AirNow's data shows. The EPA has declared the air quality in states near the Canadian border as "unhealthy or "unhealthy for sensitive groups." See maps and impacted states. See map of Canadian wildfires See map of US wildfires and smoke Which states are most affected by the Canadian fires? As of 9 a.m. ET on Tuesday, Aug. 5, areas in the following states are "Unhealthy for sensitive groups," according to AirNow: People with pre-existing medical conditions, like asthma, will be more sensitive to conditions that are deemed "Unhealthy for Sensitive Groups." "Members of sensitive groups may experience health effects," according to AirNow. 'Unhealthy' air quality States' air quality is measured by the EPA's U.S. Air Quality Index, according to AirNow's website. Values with an index of 151 to 200 are deemed unhealthy for all. As of 9 a.m. ET on Tuesday, Aug. 5, areas in the following states have been deemed unhealthy, according to AirNow's air quality map: "Some members of the general public may experience health effects," AirNow states on its website. However, "members of sensitive groups may experience more serious health effects." To learn if your area's air quality is affected by the wildfires, visit AirNow's interactive map. Side effects of inhaling wildfire smoke Wildfire smoke can irritate one's eyes, nose, and throat and cause the following symptoms: Particulate matter (PM) is one of the main components of wildfire smoke, comprised of small particles of solids or liquids suspended in the air, USA TODAY previously reported. According to Yale Medicine, the particles can be 10 micrometers, PM 10, or as small as 2.5 micrometers, PM 2.5, and the smaller one poses a lot of health risks. PM 2.5 is so tiny that it can easily pass people's usual defense mechanisms and go deep into their lungs. Not only can it damage lung function, but it can also pass into the bloodstream and travel to other organs. The following is linked to exposure to the PM 2.5: Julia is a trending reporter for USA TODAY. Connect with her on LinkedIn, X, Instagram, and TikTok: @juliamariegz, or email her at jgomez@
Miami Herald
4 hours ago
- Miami Herald
Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
RED BANK, NJ / ACCESS Newswire / August 5, 2025 / Tharimmune, Inc. (NASDAQ:THAR), ("Tharimmune" or the "Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today proudly announced the appointment of Nancy Davis, a globally recognized philanthropist, tenacious advocate, and the visionary founder of the renowned Race to Erase MS and Cure Addiction Now foundations, to its Board of Directors. Ms. Davis brings an unparalleled fusion of deep-seated patient advocacy, strategic fundraising, and a profound, personal commitment to accelerating scientific discovery in areas of critical unmet medical need. Her decades of consummate resilience and unwavering patient-centric approach, born from personal experience, make her an ideal and impactful addition to the Board. Ms. Davis's formidable journey into medical advocacy was ignited by her own diagnosis of multiple sclerosis (MS) in 1991, at the age of 33. Despite being told there was little hope, Nancy refused to accept this prognosis, proactively seeking new therapies and embracing a health-conscious lifestyle. This deeply personal challenge fueled her determination to fundamentally transform the landscape of MS research and treatment. In 1993, she established the Race to Erase MS, an organization that has since raised over $56 million, directly catalyzing groundbreaking research through its innovative "Center Without Walls" program. This pioneering initiative actively dismantles traditional research silos, fostering unprecedented collaboration among leading institutions such as UC San Francisco, Harvard, Yale, USC, Johns Hopkins, UCLA, Cedars-Sinai, and Oregon Health Sciences University. Under her visionary leadership, Race to Erase MS has funded numerous pilot studies instrumental in developing FDA-approved therapies, including the scientific discoveries in B-Cell therapies like Ocrevus®, Briumvi®, and Kesimpta®, which are now gold standards of MS treatment and have completely changed the landscape of the disease. When Nancy founded the organization, there were no FDA-approved treatments for MS but her guiding principle, "take the impossible and make it possible," perfectly encapsulates her profound impact. "Tharimmune is incredibly honored and privileged to welcome Nancy Davis to our Board," said Vincent LoPriore, Executive Chairman of the Board of Director. "Nancy's extraordinary dedication to advancing medical research, coupled with her unique and powerful perspective as both a patient advocate and a formidable force for scientific collaboration, is absolutely invaluable as we continue to develop innovative, life-saving therapies. Her vision aligns perfectly with our mission to bring life-changing solutions to patients, especially as we advance our investigational product, TH104. Our lead is being specifically developed to counter the effects of weaponized fentanyl for military use and chemical incident responders, and it may potentially hold significant promise for broader applications in addressing the devastating opioid crisis. Nancy's profound understanding of patient needs and her unwavering commitment to finding solutions for addiction make her an indispensable and critical voice on our Board. Her proven track record of converting personal adversity into global advocacy and tangible scientific progress is truly inspiring." Ms. Davis co-founded Cure Addiction Now (CAN) with her son, Jason and this pivotal foundation is dedicated to revolutionizing the understanding and treatment of substance use disorder (SUD) by funding cutting-edge, collaborative research that addresses both the physical and emotional aspects of addiction. CAN aims to find therapies that combat withdrawal and cravings, with the ultimate goal of achieving lasting sobriety. Her transformative work with CAN continues to fiercely challenge stigmas and relentlessly push for scientific breakthroughs to combat one of the most pressing public health crises of our time. "I am thrilled and deeply motivated to join the Board of Directors at Tharimmune and contribute to their ongoing, exciting work," said Nancy Davis. "Throughout my career, I've seen firsthand the profound power of focused, collaborative scientific endeavor to bring about real, tangible change for patients. I am deeply impressed by Tharimmune's commitment to developing critical countermeasures, such as TH104. My personal experiences with the devastating impact of addiction have only strengthened my resolve to support truly innovative solutions and I eagerly look forward to contributing my insights and advocacy to help accelerate the development and potential broader impact of this solution and other transformative therapies." About Tharimmune, is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick™ Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: Forward Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release. Contacts:Tharimmune, SOURCE: Tharimmune Inc.
